Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The industry is positioned for a "Davis double" effect, where both performance and valuation are expected to improve [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions, while domestic replacements continue to grow, and overseas business progresses rapidly [2]. - The neurosurgery and neurointervention fields are stabilizing after centralized procurement, with new products expected to contribute to growth [2]. Group 3: Medical Devices - The medical device sector is experiencing a high-speed growth in bidding data, with companies entering a destocking phase, which is expected to improve performance in the second half of the year [2]. - The low-value consumables sector is seeing continuous product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is increasingly concentrated among state-owned enterprises, leading to a clearer competitive landscape [2]. - The demand side is expected to upgrade towards new products, gradually improving the industry's overall health [2]. Group 5: API (Active Pharmaceutical Ingredients) - The industry is at an upward turning point due to the end of a capital expenditure peak, combined with three growth drivers: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies are expected to see explosive growth in revenue and profits in the medium term [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is seeing a revival in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs, while the retail pharmacy sector is influenced by supply-side adjustments and business model upgrades [2]. - The performance of offline pharmacies is expected to improve in the second half of 2025, with leading chains like YaoXingTang making progress in store upgrades [2]. Group 8: Research Reports - A series of in-depth research reports on various companies and sectors within the pharmaceutical and medical device industries have been published, highlighting their growth potential and market positioning [3][4].

Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [22]. Core Insights - The company reported a revenue of 787 million yuan for the first half of 2025, representing a year-on-year growth of 14.72%, with a net profit of 213 million yuan, up 2.53% [2]. - The high-end intraocular lens segment is experiencing rapid growth, and the company is accelerating its overseas market expansion [2][6]. - The company has a strong pipeline of innovative products, with several projects in the registration phase and expected to launch soon [6]. Financial Performance - For the first half of 2025, the company achieved a revenue of 787 million yuan, with a net profit of 213 million yuan, and a non-recurring net profit of 204 million yuan [2]. - The revenue for Q2 2025 was 430 million yuan, reflecting a year-on-year increase of 14.44%, while the net profit for the same period was 121 million yuan, up 14.85% [2]. - The company forecasts total revenue of 1,795 million yuan for 2025, with a year-on-year growth rate of 27.3% [7]. Business Segmentation - The high-end intraocular lens revenue reached 364 million yuan in H1 2025, growing by 9.70%, with artificial lens products contributing 345 million yuan, up 8.23% [6]. - The company’s near-sightedness prevention segment generated 166 million yuan, with a growth of 8.28%, while vision care revenue was 249 million yuan, increasing by 27.43% [6]. - Domestic revenue was 744 million yuan, up 12.37%, while overseas revenue surged by 80.10% to 43 million yuan, indicating a strong international market strategy [6]. Valuation and Price Target - The report sets a target price of 100 yuan, based on a DCF model that values the company at approximately 194 billion yuan [3][6]. - The expected earnings per share (EPS) for 2025 is projected at 2.40 yuan, with a price-to-earnings (P/E) ratio of 32 [7].

Investment Rating - The report assigns a "Buy" rating to the company [1][4][6] Core Views - The company reported a revenue of 787 million yuan in H1 2025, representing a year-on-year increase of 14.72%, and a net profit attributable to shareholders of 213 million yuan, up by 2.53% [1] - The growth in high-end crystals and soft lenses is accelerating, with a strong product pipeline continuing to advance [1][3] - The company is positioned as a leading domestic ophthalmic consumables manufacturer, benefiting from rapid growth in high-end consumables and capacity expansion in soft lenses [4] Financial Performance Summary - Revenue and Profit: In H1 2025, the company achieved a revenue of 787 million yuan (+14.72%) and a net profit of 213 million yuan (+2.53%) [1] - Gross Margin: The gross margin for H1 2025 was 65.25%, reflecting a decrease of 3.98 percentage points due to the dilution from the colored lens business [2] - Profitability Metrics: The net profit margin was 26.30% (-2.75 percentage points), and the attributable net profit margin was 27.11% (-3.22 percentage points) [2] Business Segments Performance - Artificial Lens: Revenue from the artificial lens business was 345 million yuan (+8.23%) with a gross margin of 86.42% [3] - Orthokeratology Lens: Revenue from orthokeratology lenses was 119 million yuan (+5.63%) with a gross margin of 84.76% [3] - Other Myopia Control Products: Revenue from other myopia control products was 47 million yuan (+15.58%) with a gross margin of 69.65% [3] - Contact Lens: Revenue from contact lenses was 236 million yuan (+28.89%) with a gross margin of 27.76% [3] Product Pipeline and R&D - The company has received approvals for several products, including the "Long Crystal" artificial lens and silicone hydrogel soft lenses [4] - Ongoing R&D includes EDoF artificial lenses and various types of hyaluronic acid for filling, with several products in clinical trials [4] Earnings Forecast and Valuation - The company is expected to generate revenues of 1.738 billion yuan, 2.229 billion yuan, and 2.751 billion yuan for the years 2025, 2026, and 2027, respectively [4] - Projected net profits for the same years are 454 million yuan, 574 million yuan, and 720 million yuan [4] - Corresponding P/E ratios for 2025, 2026, and 2027 are estimated at 33X, 26X, and 21X, respectively [4]

中国银河证券股份有限公司关于 爱博诺德（北京）医疗科技股份有限公司 2025 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》和《上海证券交易所上市公司自律监管指引第 11 号——持续督导（2025 年 3 月修订）》等有关法律、法规的规定，中国银河证券股份有限公司（以下简 称"保荐人"）作为正在履行爱博诺德（北京）医疗科技股份有限公司（以下简 称"爱博医疗""公司"）持续督导工作的保荐机构，出具本持续督导半年度跟 踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料；（2） 查阅公司财务管理、会计核算和内部审计等内部控制制度；（3）查阅公司与其 关联方的资金 ...

Group 1: Macro and Strategy - The report highlights the impact of the Federal Reserve's quantitative easing (QE) policies on U.S. Treasury yields, indicating that while QE provides liquidity, its long-term effects significantly lower yields [8][9]. - The report outlines four phases of the Federal Reserve's bond purchasing history, detailing the transition from traditional monetary policy to QE during the 2008 financial crisis and the COVID-19 pandemic [9][10]. - Recent economic data indicates a potential rebound in the bond market, with expectations for improved performance following the release of economic growth data on September 15 [11][12]. Group 2: Industry and Company Insights - The semiconductor industry, particularly the analog chip sector, is expected to see growth, with global market sizes projected to increase by 3.3% and 5.1% in 2025 and 2026, respectively [16][17]. - Domestic companies in the analog chip market are anticipated to benefit from increased demand in industrial, automotive, and AI applications, with significant potential for domestic market share growth [17][18]. - The renewable energy sector, particularly wind power, is experiencing favorable pricing outcomes, with competitive bidding results indicating strong investment returns for wind projects [19][20]. - Agricultural products are projected to enter a bullish cycle, with expectations for rising prices in beef and milk, driven by supply dynamics and market recovery [21][22][23]. - The report notes that the company Golden Meat Industry has seen a significant increase in profits from its beef and lamb business, despite challenges in its pig farming segment [35][36]. Group 3: Company-Specific Developments - Daikin Heavy Industries has secured a large contract worth approximately 1.25 billion yuan for offshore wind turbine foundations, which is expected to positively impact its financial performance in 2026 [24][25]. - Kelaiying, a leading CDMO in China, is expanding its service offerings and is projected to achieve steady revenue growth, with a forecasted revenue of 66.8 billion yuan in 2025 [26][28]. - Aibo Medical has reported a significant increase in net profit driven by high-end artificial crystal products, with a 30% quarter-on-quarter growth in the second quarter [29][30][31]. - Bluko is launching new products to enhance its IP portfolio, which is expected to drive revenue growth, particularly in the lower-priced market segment [33][34].

Core Viewpoint - The company reported strong revenue growth and achieved a record high profit since its listing in the second quarter of 2025, despite challenges from macroeconomic conditions and industry policies [1][4]. Financial Performance - In the first half of 2025, the company achieved revenue of 787 million (+14.72%) and a net profit attributable to shareholders of 213 million (+2.53%) [1]. - The second quarter revenue was 430 million (+14.44%), with a quarter-on-quarter growth of 20.25% [1]. - The net profit for the second quarter was 121 million (+14.85%), with a quarter-on-quarter increase of 30.46%, marking the highest quarterly profit since the company went public [1]. Product Performance - Revenue from artificial crystals reached 345 million (+8.23%), with high-end products like "All-View" multifocal intraocular lenses and "Long Crystal" intraocular lenses showing rapid growth [2]. - The "Puno Tong" orthokeratology lens generated revenue of 119 million (+5.63%), maintaining sales growth amid intensified competition and consumer downgrade [2]. - Revenue from contact lenses was 236 million (+28.89%), driven by the expansion of self-branded sales channels [2]. Profitability Metrics - The gross profit margin for the first half of 2025 was 65.25% (-4.43 percentage points), primarily affected by the increased proportion of lower-margin contact lens products [3]. - The gross profit margin for the second quarter improved to 65.80%, up 1.80 percentage points from the previous quarter [3]. - The net profit margin for the second quarter improved to 27.26%, showing both year-on-year and quarter-on-quarter improvements [3]. Product Development - The company launched the "Long Crystal" intraocular lens for correcting/reducing myopia in adults in January 2025 [3]. - Self-developed silicone hydrogel contact lenses (model: S2DRT) have been certified, and various intraocular lens projects are progressing well [3]. Investment Outlook - The company is the first domestic manufacturer to independently develop high-end refractive intraocular lenses, with a well-established myopia prevention product line and a rapidly expanding contact lens business [4]. - The first domestically produced intraocular lens, Long Crystal, has significant import substitution potential, with future platform and international development prospects [4]. - Profit forecasts for 2025-2027 have been adjusted to 427 million, 520 million, and 627 million, respectively, reflecting a year-on-year growth of 10.0%, 21.7%, and 20.5% [4].

Investment Rating - The investment rating for the company is "Outperform the Market" [5][24]. Core Views - The company has shown rapid growth in high-end artificial lens products, with a significant increase in quarterly profits, achieving a record high since its listing [1][8]. - Despite challenges from macroeconomic conditions and industry policies, the company has maintained steady revenue growth, although net profit growth has lagged behind revenue growth due to lower margins from certain products [1][8]. - The company is the first domestic manufacturer to independently develop high-end refractive artificial lenses, with a well-established myopia prevention product line and significant potential for platform and international development [24]. Financial Performance - In the first half of 2025, the company achieved revenue of 787 million (up 14.72%) and a net profit of 213 million (up 2.53%), with a record quarterly net profit of 121 million in Q2, reflecting a 30.46% increase quarter-on-quarter [1][8]. - The gross profit margin for the first half of 2025 was 65.25%, impacted by a higher proportion of lower-margin products, while the net profit margin improved to 27.26% in Q2 [3][19]. - The company’s operating cash flow remained healthy, with a net cash flow from operating activities of 154 million (up 26.43%) in the first half of 2025 [19]. Business Segments - Revenue from artificial lenses reached 345 million (up 8.23%), with high-end products like "Longjing" and "All-View" lenses seeing rapid growth [2][14]. - The myopia prevention product line, particularly the "Punotong" corneal shaping lens, generated 119 million (up 5.63%), maintaining sales growth amid increased competition [2][14]. - The contact lens segment reported revenue of 236 million (up 28.89%), driven by the expansion of self-branded sales channels [2][14]. Future Outlook - The company has revised its profit forecasts for 2025-2027, now expecting net profits of 427 million, 520 million, and 627 million, respectively, with year-on-year growth rates of 10.0%, 21.7%, and 20.5% [24]. - The current stock price corresponds to a price-to-earnings ratio (PE) of 35.9, 29.5, and 24.4 for the years 2025, 2026, and 2027, respectively [24].

Core Viewpoint - Aibo Medical (688050.SH) has confirmed that its existing products do not involve the brain-computer interface (BCI) field [1] Group 1 - The company stated that its current product offerings are not related to brain-computer interfaces [1] - Aibo Medical encourages stakeholders to monitor its regular reports and announcements for updates on its research and development progress [1]

Investment Rating - The investment rating for the company is "Buy" [5] Core Views - The company reported a steady growth in revenue and profit in Q2 2025, with a revenue of 430 million yuan, up 14.44% year-on-year, and a net profit of 121 million yuan, up 14.85% year-on-year [1][2] - The company is experiencing improvements in the yield of contact lenses and is expected to see a ramp-up in high-end new products [2] - The gross margin decreased to 65.80% in Q2 2025, primarily due to the impact of centralized procurement policies and an increase in the proportion of low-margin contact lens products [2] Financial Performance - For H1 2025, the company achieved a revenue of 787 million yuan, a year-on-year increase of 14.72%, and a net profit of 213 million yuan, a year-on-year increase of 2.53% [1] - The revenue breakdown for H1 2025 includes contact lenses at 236 million yuan (up 28.89%), intraocular lenses at 345 million yuan (up 8.23%), and orthokeratology lenses at 119 million yuan (up 5.63%) [2] - The company’s domestic revenue reached 744 million yuan (up 12.37%), while overseas revenue surged to 43 million yuan (up 80.10%) [3] Market Position and Strategy - The company is enhancing its domestic sales channels and steadily advancing its overseas market layout, with a sales network covering over 6000 hospitals and vision centers across 31 provinces and municipalities in China [3] - The company has established a global sales network, exporting products to over 30 countries, including Germany, France, and the UK [3] - The company’s high-end products, such as the "All-View" multifocal intraocular lenses, are gaining rapid market acceptance, contributing to the growth of its product mix [2] Earnings Forecast - The company is projected to achieve revenues of 1.683 billion yuan, 2.112 billion yuan, and 2.662 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 19.4%, 25.5%, and 26.1% [4] - The forecasted net profits for the same years are 445 million yuan, 545 million yuan, and 667 million yuan, with growth rates of 14.7%, 22.4%, and 22.4% [4]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][41]. Core Views - The pharmaceutical sector has shown resilience, outperforming the overall market with a 1.40% increase, while the total A-share market declined by 1.17% [1][32]. - ANGPTL3 has gained significant interest from multinational pharmaceutical companies (MNCs) due to its unique mechanism of action, which is non-LDLR dependent, making it effective in patients with LDLR deficiencies [3][30]. - The report highlights the diverse drug forms targeting ANGPTL3, with MNCs like Novartis, Lilly, Amgen, and AstraZeneca actively investing in this area, indicating a potential for multi-target and multi-drug combinations in the future [3][16]. Summary by Sections Market Performance - The overall A-share market fell by 1.17%, with the Shanghai and Shenzhen 300 index down by 0.81%. The biotechnology sector, however, rose by 1.40%, indicating strong performance relative to the broader market [1][32]. - Specific segments within the pharmaceutical sector showed varied performance, with chemical pharmaceuticals up by 3.92% and medical services up by 1.69%, while medical devices and traditional Chinese medicine saw declines [1][32]. ANGPTL3 Developments - A collaboration between Argo Biopharma and Novartis was announced, focusing on RNA drugs for cardiovascular diseases, with a total potential payment of $5.2 billion, including a $160 million upfront payment [2][11]. - ANGPTL3's mechanism allows for significant reductions in LDL-C levels in patients with HoFH, outperforming traditional treatments like PCSK9 inhibitors [3][31]. Company Earnings Forecasts and Ratings - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, have been rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion yuan [4][41]. - The report provides detailed earnings forecasts for various companies, indicating a positive outlook for the sector as a whole [4][41]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 40.75x, significantly higher than the overall A-share market's 19.80x [37][38]. - Sub-sectors such as chemical pharmaceuticals and biological products have even higher valuations, indicating strong investor interest and growth potential [37][38]. Recommended Stocks - The report recommends several companies, including Mindray Medical for its strong market position and international expansion, WuXi AppTec for its comprehensive drug development services, and Aier Eye Hospital for its leading position in the eye care sector [41][42].